Helixmith Obtains Domestic Patent for 'HX112,' a Substance for Prevention and Treatment of Metabolic Bone Diseases and Menopausal Symptoms

[Asia Economy Reporter Jang Hyowon] Helixmith announced on the 24th that it has obtained a domestic patent for ‘HX112,’ a substance for the prevention and treatment of metabolic bone diseases and menopausal symptoms.

HX112 is a material developed by Helixmith using domestically sourced medicinal crops. Through non-clinical studies, two types of medicinal crops showing excellent efficacy in various symptom indicators that may appear in female menopause, such as vascular stiffness, hot flashes, and osteoporosis, were selected and optimally blended to produce a synergistic effect.

In particular, in April, HX112 was recognized for its technological value by being selected for the ‘2021 Technology Commercialization Support Project’ by the Korea Institute of Planning and Evaluation for Technology in Food, Agriculture, Forestry and Fisheries (IPET). The business goal is to develop a health functional food for menopausal women using domestically sourced medicinal crops proven to improve circulatory disorders, with research and development planned until the end of 2023. During the project period, Helixmith aims to complete the application for individual recognition of the raw material for health functional food approval from the Korean Ministry of Food and Drug Safety through human application trials for female menopause.

Helixmith is developing treatments targeting diseases with high unmet medical needs. In addition to biopharmaceuticals including plasmid DNA, CAR-T, and AAV-based gene therapies, the company is continuously discovering and developing natural material-based substances and technologies. Since natural materials act through complex mechanisms, selecting target diseases is important.

Yoo Seungshin, CEO of Helixmith, stated, “HX112 is highly anticipated as an excellent material that can prevent and treat symptoms that may appear during menopause for women’s healthy aging. We plan to devote all efforts to the development of treatments and materials based on various technologies to treat patients suffering from various diseases and improve their quality of life.”

This content was produced with the assistance of AI translation services.